Arcline Investment, a growth-oriented private equity firm, completed the acquisition of Polypeptide Therapeutic Solutions, a company focused on design and manufacturing of polyamino-acid, from Columbus Venture, an early-stage venture capital investment firm. Financial terms were not disclosed. "Arcline is the right partner for us at a critical time when we must invest to meet our customers' needs for scale in GMP production. They quickly saw the potential for our PAA technology platform to enable safer and more precise drug delivery. We look forward to working with them to expand our manufacturing footprint, accelerate our business development efforts, and bring new technologies to commercial scale," Jose Vicente Pons Andreu, PTS CEO.